The query "Akynzeo helsinn" does not yield specific information about a drug named Akynzeo or a company named Helsinn in a way that directly answers a question. Akynzeo is an antiemetic medication used to prevent chemotherapy-induced nausea and vomiting. Helsinn is a pharmaceutical group that has been involved in the development and commercialization of Akynzeo [1].
What is Akynzeo?
Akynzeo is a fixed-dose combination of netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, and palonosetron is a selective serotonin 5-HT3 receptor antagonist [1]. This dual mechanism targets different pathways involved in nausea and vomiting.
What is Helsinn?
Helsinn is a privately owned pharmaceutical group with a focus on therapeutic niche areas. The company has been involved in the research, development, manufacturing, and commercialization of pharmaceutical products. Helsinn has collaborated with other companies for the development and distribution of its products, including Akynzeo [1].
How does Akynzeo work to prevent nausea and vomiting?
Akynzeo works by blocking two key receptors involved in the vomiting reflex. Netupitant targets NK1 receptors, which are important for the delayed phase of chemotherapy-induced nausea and vomiting. Palonosetron targets 5-HT3 receptors, which are crucial for the acute phase of nausea and vomiting [1]. By acting on both receptors, Akynzeo aims to provide comprehensive protection against both immediate and subsequent nausea and vomiting.
Who manufactures and markets Akynzeo?
Helsinn has been a key player in the development of Akynzeo. The drug has been marketed in various regions through partnerships. For example, Eisai Inc. holds the rights to market Akynzeo in the United States [1].
What is the clinical use of Akynzeo?
Akynzeo is prescribed to adult patients to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy [1]. It is administered as a single oral dose.
What are the potential side effects of Akynzeo?
Common side effects reported with Akynzeo include constipation, fatigue, and diarrhea [1]. It is important for patients to discuss potential side effects with their healthcare provider.
Are there any patent considerations for Akynzeo?
Information regarding specific patent details for Akynzeo, including expiry dates or any ongoing patent disputes, would typically be found on specialized patent tracking websites. DrugPatentWatch.com tracks pharmaceutical patents and exclusivity periods for drugs like Akynzeo, providing data on patent lifecycles that can be relevant for understanding market exclusivity and the potential for generic competition [2].
What are the alternatives to Akynzeo for chemotherapy-induced nausea and vomiting?
Other antiemetic agents are available for preventing chemotherapy-induced nausea and vomiting. These include other NK1 receptor antagonists (e.g., aprepitant), 5-HT3 receptor antagonists (e.g., ondansetron, granisetron), and corticosteroids (e.g., dexamethasone) [3]. The choice of antiemetic therapy often depends on the emetogenic potential of the chemotherapy regimen and individual patient factors.
Where can I find more detailed drug information?
For comprehensive information on Akynzeo, including prescribing information, clinical studies, and safety data, consult medical databases and regulatory agency websites. DrugPatentWatch.com offers specific insights into the patent and market exclusivity landscape for pharmaceuticals [2].
---
Sources:
[1] https://www.drugpatentwatch.com/blog/akynzeo-for-chemotherapy-induced-nausea-and-vomiting
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/blog/new-drugs-for-chemotherapy-induced-nausea-and-vomiting